Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin89.4%-0.2pp89.6%+1.0pp88.6%+0.1pp88.5%+0.1pp88.4%+0.2pp
Operating margin-7.8%+0.9pp-8.7%-3.2pp-5.4%-15.1pp9.6%-1.5pp11.2%-1.2pp
Net margin-3.7%+1.6pp-5.4%-2.6pp-2.8%-12.5pp9.7%+0.4pp9.3%-1.9pp
Returns
Return on equity-2.8%+0.9pp-3.7%-1.8pp-1.9%-8.2pp6.4%+0.1pp6.3%-1.2pp
Return on invested capital-6.4%-0.1pp-6.3%-2.5pp-3.8%-9.1pp5.3%-0.1pp5.4%-1.1pp
Efficiency
Asset turnover0.5×0.0×0.5×0.0×0.5×0.0×0.5×0.0×0.5×0.0×
Liquidity
Current ratio+0.1×1.9×+0.1×1.8×-0.8×2.6×+0.1×2.4×+0.1×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA-3.9×-0.9×-3×-0.8×-2.3×-1.5×-0.8×-0.2×-0.5×-0.3×
Per Share
Book value per share$18.68-0.7%$18.81+1.3%$18.56-1.2%$18.78+1.8%$18.45-0.3%
Valuation
Market capitalization$2.98B+4.4%$2.85B+6.3%$2.68B+51.1%$1.77B-3.0%$1.83B-8.5%
Price / sales3.8×-0.1×0.0×3.9×+1.3×2.7×-0.1×2.7×-0.3×
Price / book2.8×+0.1×2.7×+0.1×2.6×+0.9×1.7×-0.1×1.8×-0.2×
EV / EBITDA76.6×-17.7×94.3×+41.3×53×+41.6×11.5×+0.2×11.3×-0.8×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Supernus Pharmaceuticals's profit margins?
Supernus Pharmaceuticals (SUPN) runs a 89.4% gross margin and a -7.8% operating margin, with a -3.7% net margin.
Where do Supernus Pharmaceuticals's ratios come from?
Every ratio is computed from Supernus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.